Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Currently LY2784544 is being investigated in a clinical trial for the treatment of essential thrombocythemia
1 or 10 mg/kg
23H2/t9-/m1/s1
David Brown
BLZ945 xyzine D4 dihydrochloride Currently LY2784544 is being investigatedBLZ945 is a potent and selective CSF 1R kinase inhibitor. BLZ945 showed effects of CSF1R inhibition on other tumor infiltrating immune cells. BLZ945 attenuates the turnover rate of TAMs while increasing the number of CD8+ T cells that infiltrate cervical and breast carcinomas. BLZ945 decreases the growth of malignant cells in the mouse mammary tumor virus driven polyomavirus middle T antigen (MMTV PyMT) model of mammary carcinogenesis. BLZ945 prevents